Suradi Hussam S, Hijazi Ziyad M
Interventional Cardiology, Structural Heart & Valve Center, St. Mary Medical Center, 1500 South Lake Park Avenue, Suite 100, Hobart, IN 46342, USA; Department of Cardiology, Community Hospital, Munster, IN 46321, USA; Rush Center for Structural Heart Disease, Rush University Medical Center, Chicago, IL 60612, USA.
Sidra Cardiac Program, Department of Pediatrics, Sidra Medical & Research Center, Weill Cornell Medicine, PO Box 26999, Doha, Qatar.
Interv Cardiol Clin. 2017 Jul;6(3):427-443. doi: 10.1016/j.iccl.2017.03.011.
Congenital heart disease (CHD) is the most common birth defect, occurring in approximately 0.8% to 1.0% of neonates. Advances in medical and surgical therapies for children with CHD have resulted in a growing population of patients reaching adulthood, with survival rates exceeding 85%. Many of these patients, especially if managed inappropriately, face the prospect of future complications including heart failure and premature death. For adults with uncorrected or previously palliated CHD, percutaneous therapies have become the primary treatment for many forms of CHD. In this article, we discuss the role of transcatheter interventions in the treatment of adults with CHD.
先天性心脏病（CHD）是最常见的出生缺陷，约0.8%至1.0%的新生儿患有该病。儿童先天性心脏病医学和外科治疗的进展使成年患者数量不断增加，存活率超过85%。这些患者中许多人，尤其是治疗不当者，面临着包括心力衰竭和过早死亡在内的未来并发症风险。对于未矫正或先前已姑息治疗的成年先天性心脏病患者，经皮治疗已成为多种先天性心脏病的主要治疗方法。在本文中，我们讨论经导管介入治疗在成年先天性心脏病患者治疗中的作用。
